Anthony Starpoli, MD
Gastroenterology · Poughkeepsie, NYNPI 1477633642
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Phathom Pharmaceuticals, Inc. accounts for 88.3% of it on its own, with 24 other manufacturers making up the rest. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $317.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$47K
- Capsovision, Inc.$1K
- QOL Medical, LLC$879
- Novo Nordisk$642
- Endogastric Solutions, Inc$610
- Olympus America Inc.$439
- plus $2K from 19 others
What the payments were for
- Consulting fees$1,6503%
- Speaking & faculty fees$31,75060%
- Travel & lodging$13,90626%
- Food & beverage$5,73511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 42 | $46,829 |
| Capsovision, Inc. | 2 | $1,400 |
| QOL Medical, LLC | 38 | $879 |
| Novo Nordisk | 19 | $642 |
| Endogastric Solutions, Inc | 4 | $610 |
| Olympus America Inc. | 5 | $439 |
| Micro-tech Endoscopy USA, Inc. | 3 | $382 |
| Boston Scientific | 4 | $287 |
| Covidien LP | 4 | $233 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $151 |
| Lilly USA, LLC | 7 | $151 |
| Medtronic | 1 | $147 |
| Steris Corporation | 1 | $144 |
| Redhill Biopharma Inc. | 6 | $136 |
| Madrigal Pharmaceuticals | 5 | $124 |
| Merck | 6 | $122 |
| AbbVie | 3 | $86 |
| 3-d Matrix, Inc. | 1 | $66 |
| Bristol Myers Squibb | 2 | $62 |
| Lucid Diagnostics Inc. | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Ambu Inc. | 1 | $21 |
| Celltrion USA Inc. | 1 | $20 |
| Merz North America, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$46,220
- ESOPHYX$524
- Wegovy$365
- LesionHunter$200
- SureClip and Traction Device$170
- Endocuff Vision$149
- DISPOSABLE TRIPLE LUMEN SPHINCTEROTOME$149
- Single Use Electrosurgical Knife KD-655$149
- Single Use Electrosurgical Hemostatic Forceps$149
- GI Genius$147
- TRUFREEZE$144
- VISIGLIDE$116
How this compares
$53,041 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 26 | $28,112 |
| VoqueznaVonoprazan Fumarate | 14 | $7,995 |
| Dexlansoprazole DrDexlansoprazole | 12 | $3,949 |
| Ursodiol | 13 | $3,560 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 11 | $1,892 |
| Omeprazole | 104 | $1,522 |
| Rabeprazole Sodium | 25 | $1,019 |
| Famotidine | 42 | $909 |
| Esomeprazole Magnesium | 11 | $571 |
| Pantoprazole Sodium | 23 | $441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $86 | $28,11226 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $46,829 | $7,99514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in Poughkeepsie
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.